Esperion Therapeutics (ESPR) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View ESPR analyst ratings or view top-rated stocks.

9 brokerages have issued twelve-month price targets for Esperion Therapeutics' stock. Their ESPR share price forecasts range from $1.50 to $22.00. On average, they predict the company's share price to reach $11.17 in the next twelve months. This suggests a possible upside of 664.8% from the stock's current price.
View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts.

Esperion Therapeutics' stock was trading at $6.23 on January 1st, 2023. Since then, ESPR shares have decreased by 76.6% and is now trading at $1.46.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our ESPR earnings forecast.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.14. The biopharmaceutical company earned $24.30 million during the quarter, compared to analyst estimates of $21.97 million. The company's revenue for the quarter was up 29.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.93) EPS.

ETFs with the largest weight of Esperion Therapeutics (NASDAQ:ESPR) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Esperion Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (17.44%), Balyasny Asset Management L.P. (5.04%), Meditor Group Ltd (4.94%), Armistice Capital LLC (3.88%), Platinum Investment Management Ltd. (3.37%) and State Street Corp (2.01%). Insiders that own company stock include Benjamin Looker, Eric Warren, J Martin Carroll, Joanne M Foody, Sheldon L Koenig and Target N V Biotech.
View institutional ownership trends.

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ESPR stock can currently be purchased for approximately $1.46.

Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $138.28 million and generates $75.47 million in revenue each year. The biopharmaceutical company earns $-233,660,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis.

The company employs 218 workers across the globe.

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com.